Losartan and HCTZ and Amlodipine vs Atenolol and Amlodipine - Full Text View

Sponsor:	Merck
Information provided by:	Merck
ClinicalTrials.gov Identifier:	NCT00140959

Purpose

A study to evaluate the effects of combination losartan versus combination atenolol in patients with ambulatory systolic hypertension.

Condition	Intervention	Phase
Hypertension	Drug: MK0954, losartan potassium/Duration of Treatment: 18 weeks Drug: Comparator: losartan, HCTZ, amlodipine, atenolol/Duration of Treatment: 18 weeks	Phase IV

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	Antihypertensive Effects of a Fixed-Dose Combination of Losartan and Hydrochlorothiazide Plus Amlodipine Versus a Hydrochlorothiazide and Atenolol Combination Plus Amlodipine in Subjects With Ambulatory Systolic Hypertension.

Resource links provided by NLM:

MedlinePlus related topics: Blood Pressure Medicines High Blood Pressure

Drug Information available for: Hydrochlorothiazide Atenolol Amlodipine Amlodipine besylate Losartan Losartan potassium

U.S. FDA Resources

Further study details as provided by Merck:

Primary Outcome Measures:

Mean daytime ambulatory systolic blood pressure

Secondary Outcome Measures:

Ambulatory BP
Pulse pressure
Trough sitting BP
Percentage of patients who reach goal ambulatory systolic BP

Estimated Enrollment:	120
Study Start Date:	February 2003

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Males or females at least 18 years of age who have ambulatory systolic hypertension.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00140959

Sponsors and Collaborators

Merck

Investigators

Study Director:

Medical Monitor

Merck

More Information

Publications:

Lacourcière Y, Poirier L, Lefebvre J. Expedited blood pressure control with initial angiotensin II antagonist/diuretic therapy compared with stepped-care therapy in patients with ambulatory systolic hypertension. Can J Cardiol. 2007 Apr;23(5):377-82.

Responsible Party:	Merck & Co., Inc. ( Executive Vice President, Clinical and Quantitative Sciences )
Study ID Numbers:	2005_061, MK0954-309
Study First Received:	August 31, 2005
Last Updated:	February 27, 2009
ClinicalTrials.gov Identifier:	NCT00140959 History of Changes
Health Authority:	Canada: Health Canada

Additional relevant MeSH terms:

Vasodilator Agents
Neurotransmitter Agents
Adrenergic Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Diuretics
Sodium Chloride Symporter Inhibitors
Calcium Channel Blockers
Membrane Transport Modulators
Therapeutic Uses
Adrenergic beta-Antagonists
Cardiovascular Diseases
Anti-Arrhythmia Agents
Sympatholytics

Losartan
Vascular Diseases
Cardiovascular Agents
Antihypertensive Agents
Hydrochlorothiazide
Pharmacologic Actions
Amlodipine
Angiotensin II Type 1 Receptor Blockers
Autonomic Agents
Natriuretic Agents
Adrenergic Antagonists
Peripheral Nervous System Agents
Atenolol
Hypertension

ClinicalTrials.gov processed this record on February 08, 2010